CTOs on the Move

Ambys

www.ambys.com

 
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ambys.com
  • 131 Oyster Point Boulevard Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.481.7662

Executives

Name Title Contact Details
Alan Smith
 Chief Technology Officer Profile

Funding

Ambys raised $60M on 08/08/2018
Ambys raised $80M on 08/08/2018

Similar Companies

Nile Therapeutics

Nile Therapeutics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bioStrategies Group

bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rezolute

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.

Biostar Ventures

BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.